6.4 FeNO, Methacholine Challenge & Allergy Testing Modalities

Certified Asthma Educator AE-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AE-C Examination 1.2 How to Use This Study Guide

2 Chapter 2: Anatomy, Physiology & Airway Pathophysiology

2.1 Normal vs. Asthmatic Airway Architecture 2.2 Cellular Inflammation, Mediators & Airway Remodeling 2.3 Bronchial Hyperresponsiveness & Airflow Obstruction Mechanics

3 Chapter 3: Triggers, Exposures & Phenotypes

3.1 Aeroallergens & Allergic Sensitization Mechanisms 3.2 Non-Allergic Irritants & Environmental Airborne Hazards 3.3 Respiratory Infections, Exercise & Physiological Stressors 3.4 Asthma Phenotypes, Endotypes & Lifespan Variations 3.5 Genetics, Family History & Early-Life Determinants

4 Chapter 4: Comorbidities, Medications & Asthma Mimics

4.1 Upper Airway Diseases & Gastroesophageal Reflux 4.2 Systemic Comorbidities, Obesity & Adverse Drug Reactions 4.3 Differential Diagnosis & Major Asthma Mimics

5 Chapter 5: Clinical History & Physical Assessment

5.1 Comprehensive Asthma History & Risk Stratification 5.2 Physical Examination, Auscultation & Atopic Stigmata 5.3 Acute Exacerbation Severity Triage & Life-Threatening Red Flags 5.4 Criteria for Specialist Referral & Advanced Consultation 5.5 Medication Reconciliation & Integrating the Medical Record

6 Chapter 6: Diagnostic Testing & Pulmonary Function

6.1 Spirometry Principles, Maneuvers & ATS/ERS Quality Criteria 6.2 Bronchodilator Reversibility Testing Protocols & Interpretation 6.3 Peak Expiratory Flow Monitoring & Personal Best Determination 6.4 FeNO, Methacholine Challenge & Allergy Testing Modalities

7 Chapter 7: Severity, Control & Psychosocial Evaluation

7.1 Asthma Severity Classification (NHLBI EPR-3 & GINA) 7.2 Asthma Control Assessment Tools & Validated Questionnaires 7.3 Health Literacy, Educational Needs Assessment & Plain Language Principles 7.4 Psychosocial, Cultural & Family Dynamics in Self-Management

8 Chapter 8: Reliever Medications & Bronchodilators

8.1 Short-Acting Beta-2 Agonists (SABAs) & Cellular Mechanisms 8.2 SABA Overuse, Paradoxical Hyperresponsiveness & Safety Warnings 8.3 Short-Acting Muscarinic Antagonists (SAMAs) & Acute Adjunctive Therapy 8.4 SMART/MART & Anti-Inflammatory Reliever (AIR) Regimens

9 Chapter 9: Inhaled Corticosteroids & Combination Therapies

9.1 Inhaled Corticosteroids: Pharmacology, Potency & Dosing 9.2 ICS Adverse Effects, Systemic Safety & Dispelling Steroid Phobia 9.3 Long-Acting Beta-2 Agonists & Fixed-Dose Combination Inhalers 9.4 Stepwise Pharmacotherapy Guidelines (Age-Stratified Step-Up & Step-Down)

10 Chapter 10: Additional Controllers & Biologic Therapies

10.1 Leukotriene Modifiers & 5-Lipoxygenase Inhibitors 10.2 Long-Acting Muscarinic Antagonists (LAMAs) & Alternative Controllers 10.3 Monoclonal Antibodies & Biologic Therapies for Severe Asthma 10.4 Systemic Corticosteroids, Adrenal Safety & Immunizations 10.5 Allergen Immunotherapy, Intranasal Therapy & Treating Comorbidities

11 Chapter 11: Inhalation Devices & Delivery Mechanics

11.1 Pressurized Metered-Dose Inhalers (pMDIs) & Valved Holding Chambers 11.2 Dry Powder Inhalers (DPIs): Mechanics, Resistance & Technique 11.3 Soft Mist Inhalers (SMIs) & Small-Volume Nebulizers (SVNs) 11.4 Device Selection Algorithm, Patient Capabilities & Technique Assessment 11.5 Over-the-Counter, Alternative & Complementary Therapies

12 Chapter 12: Environmental Control & Behavioral Interventions

12.1 Evidence-Based Indoor Allergen Mitigation & Integrated Pest Management 12.2 Tobacco Cessation, Electronic Nicotine Systems & Irritant Elimination 12.3 Exercise-Induced Bronchoconstriction (EIB) Management & Sports Participation 12.4 Behavioral Counseling, Motivational Interviewing & Adherence Enhancement 12.5 Social, Economic & Substance-Use Barriers to Self-Management

13 Chapter 13: Action Plans, Exacerbations & Continuing Care

13.1 Written Asthma Action Plans & the Traffic-Light Zone System 13.2 School, Workplace & Childcare Action Plans 13.3 Home & Outpatient Acute Exacerbation Protocols 13.4 Periodic Reevaluation, Step-Down & Post-Discharge Follow-Up 13.5 Designing the Individualized Self-Management Education Plan 13.6 Coaching Decision-Making, Confidence & Documenting Mastery

14 Chapter 14: Program Needs Assessment & Implementation

14.1 Epidemiological Analysis & Community Needs Assessment 14.2 Evidence-Based Asthma Interventions & CDC EXHALE Strategies 14.3 Program Design, Multidisciplinary Staffing & Operational Workflows

15 Chapter 15: Evaluation, Ethics, Quality & Health Systems

15.1 Legal, Ethical, HIPAA/FERPA & Clinical Documentation Standards 15.2 Program Evaluation, CQI Methodologies & Outcome Metrics 15.3 Interprofessional Partnerships, Advocacy & Reimbursement Pathways

6.4 FeNO, Methacholine Challenge & Allergy Testing Modalities

Key Takeaways Explain This Topic AI

Fractional exhaled Nitric Oxide (FeNO) is a non-invasive quantitative biomarker reflecting Type 2 (T2-high) eosinophilic airway inflammation driven by IL-4 and IL-13 induction of inducible nitric oxide synthase (iNOS).

ATS consensus cutoffs in adults define FeNO <25 ppb as low (eosinophilic inflammation unlikely), 25 to 50 ppb as intermediate, and >50 ppb as high (>35 ppb in children), confirming active Type 2 inflammation and predicting robust corticosteroid responsiveness.

Valid FeNO testing requires a constant exhalation flow rate of 50 mL/s for 10 seconds (6 seconds in children) and MUST be performed before spirometry or exercise, with pre-test avoidance of dietary nitrates, caffeine, and smoking.

Methacholine challenge testing assesses airway hyperresponsiveness when baseline spirometry is normal; a provocative concentration causing a 20% decline in FEV1 (PC20) ≤8 mg/mL confirms hyperresponsiveness, while PC20 >16 mg/mL has a >95% negative predictive value ruling out asthma.

Allergy testing identifies IgE-mediated allergic sensitization: skin prick testing (SPT) provides rapid in vivo results but requires withholding antihistamines for 3 to 7 days, whereas serum specific IgE (sIgE) in vitro assays are unaffected by medications, severe eczema, or anaphylaxis risk.

Last updated: September 2026

6.4 FeNO, Methacholine Challenge & Allergy Testing Modalities

Quick Answer: When spirometry is inconclusive, advanced diagnostic modalities establish airway biology. FeNO measures Type 2 eosinophilic airway inflammation driven by IL-4/IL-13: levels >50 ppb in adults (>35 ppb in children) confirm eosinophilic inflammation and predict steroid responsiveness, while levels <25 ppb make eosinophilia unlikely. FeNO must be measured BEFORE spirometry. Methacholine challenge tests airway hyperresponsiveness; a PC20 ≤8 mg/mL confirms asthma, while PC20 >16 mg/mL carries a >95% negative predictive value ruling it out (contraindicated if baseline FEV1 <60%). Allergy testing (skin prick vs. serum specific IgE) identifies phenotypic allergic triggers.

While spirometry and bronchodilator reversibility testing provide crucial physiological assessments of airflow limitation, they cannot directly quantify airway wall inflammation or evaluate airway hyperresponsiveness in patients whose baseline lung function is normal. In clinical practice, asthma educators frequently encounter diagnostic dilemmas: patients with classic episodic symptoms who exhibit normal spirometry in clinic, individuals with atypical chronic cough, or patients whose symptoms persist despite high-dose inhaled corticosteroids. Resolving these challenges requires specialized diagnostic modalities: Fractional Exhaled Nitric Oxide (FeNO) , bronchoprovocation challenge testing , and aeroallergen sensitization testing .

Fractional Exhaled Nitric Oxide (FeNO): Biology & Clinical Applications

FeNO is an objective, non-invasive biomarker that measures the fractional concentration of nitric oxide gas in exhaled breath, expressed in parts per billion (ppb) . It serves as a direct surrogate marker for Type 2 (T2-high) eosinophilic airway inflammation . The Molecular Biology of FeNO Production:

Inhaled Aeroallergens / Environmental Insults
│
▼
Dendritic Cell Presentation ──► Activation of Th2 Lymphocytes & ILC2 Cells
│
▼
Secretion of Type 2 Cytokines (IL-4 and IL-13)
│
▼
Binding to IL-4 Receptor-Alpha (IL-4Rα) on Bronchial Epithelial Cells
│
▼
Transcriptional Upregulation of Inducible Nitric Oxide Synthase (iNOS / NOS2)
│
▼
iNOS oxidizes L-Arginine ──► L-Citrulline + NITRIC OXIDE (NO)
│
▼
NO Gas diffuses into the airway lumen ──► Quantified in exhaled breath via chemiluminescence (ppb)
Clinical Utility of FeNO Testing

According to the American Thoracic Society (ATS) guidelines and NAEPP 2020 Focused Updates, FeNO provides clinical value across four core domains:

Diagnostic Confirmation: Supporting an asthma diagnosis in patients with suggestive symptoms and equivocal or normal spirometry.

Predicting Corticosteroid Responsiveness: High FeNO indicates steroid-naive or undertreated eosinophilic inflammation that is highly likely to respond favorably to initiation or escalation of inhaled corticosteroids (ICS).

Monitoring Medication Adherence: A patient with persistent symptoms and a high FeNO who is prescribed an ICS should experience a dramatic drop in FeNO (typically by >20% or >10–15 ppb) within 2 to 4 weeks if adherent. A persistently elevated FeNO points toward medication non-adherence, faulty inhaler technique, or ongoing high allergen exposure.

Phenotyping for Biologic Therapies: Guiding the selection of targeted biologic monoclonal antibodies for severe asthma. Specifically, elevated FeNO (>20–25 ppb) predicts a robust clinical response to dupilumab (anti-IL-4Rα) and tezepelumab (anti-TSLP).

ATS FeNO Interpretation Cutoffs Clinical Interpretation Tiers for FeNO:

┌─────────────────────────────────────────────────────────────────────────────┐
│ LOW FeNO (<25 ppb in adults; <20 ppb in children under 12) │
│ • Eosinophilic airway inflammation is unlikely │
│ • Unresponsive or poorly responsive to corticosteroid escalation │
│ • Investigate alternative causes: GERD, VCD/ILO, cough-variant non-T2 │
└─────────────────────────────────────────────────────────────────────────────┘
│
┌─────────────────────────────────────────────────────────────────────────────┐
│ INTERMEDIATE FeNO (25 to 50 ppb in adults; 20 to 35 ppb in children) │
│ • Cautionary zone: clinical correlation mandatory │
│ • Interpret in context of symptoms, atopy, baseline therapy, and smoking │
└─────────────────────────────────────────────────────────────────────────────┘
│
┌─────────────────────────────────────────────────────────────────────────────┐
│ HIGH FeNO (>50 ppb in adults; >35 ppb in children under 12) │
│ • Confirms active Type 2 eosinophilic airway inflammation │
│ • High likelihood of clinical responsiveness to ICS initiation or step-up │
│ • Indicates increased risk of future exacerbations and rapid FEV1 decline │
└─────────────────────────────────────────────────────────────────────────────┘
Technical Standardization and Confounding Factors in FeNO

FeNO measurements are extraordinarily sensitive to exhalation aerodynamics and environmental factors. To obtain valid results, educators must enforce strict technical standards:

1. Standardization of Flow Rate and Velum Closure

Exhaled NO concentration is inversely proportional to exhalation flow velocity. Therefore, international standards mandate a strictly controlled flow rate of 50 mL/second (0.05 L/s ±10%) against a positive expiratory backpressure of 5 to 20 cm H2O :

Standardized exhalation must be maintained continuously for 10 seconds in adults (and at least 6 seconds in children under age 10 ).

The positive backpressure is mandatory to close the palatoglossal velum (soft palate) , preventing contamination from the nasopharynx. The paranasal sinuses produce physiological NO concentrations exceeding 1,000 to 2,000 ppb; any nasal leakage into the oral sample completely invalidates the test.

2. The Critical Testing Sequence Rule

MANDATORY PROTOCOL: FeNO MUST always be performed BEFORE forced spirometry, peak flow measurements, or exercise testing. Forced exhalations and transient airway shear stress cause acute, transient decreases in airway NO release that can suppress FeNO for up to 30 to 60 minutes.

3. Confounding Variables and Pre-Test Instructions

Factors that Falsely ELEVATE FeNO: Allergic rhinitis with pollen exposure (nasal contamination), active viral upper respiratory tract infections, and consumption of dietary nitrates (beets, spinach, arugula, lettuce, celery, and cured meats) within 2 to 3 hours prior to testing.

Factors that Falsely DEPRESS FeNO: Cigarette smoking and vaping (chronic tobacco smoke exposure profoundly downregulates epithelial iNOS, suppressing FeNO by 30% to 50% even in active eosinophilic asthma), recent ingestion of caffeine or alcohol , concurrent systemic or inhaled corticosteroids, and acute bronchoconstriction.

Bronchoprovocation Testing: The Methacholine Challenge

When a patient experiences episodic, exercise-induced, or nocturnal asthma symptoms but demonstrates completely normal baseline spirometry and absent bronchodilator reversibility in clinic, bronchial challenge testing is indicated to objectively assess airway hyperresponsiveness (AHR) . Methacholine Challenge Procedural Architecture:

Baseline Spirometry (FEV1 must be ≥60% predicted to proceed safely)
│
▼
Inhalation of Aerosolized Diluent (0.9% Normal Saline) ──► Repeat FEV1 (Post-Diluent Baseline)
│
▼

Sequential Inhalation of Doubling Methacholine Concentrations:

[0.031 → 0.0625 → 0.125 → 0.25 → 0.5 → 1.0 → 2.0 → 4.0 → 8.0 → 16.0 mg/mL]
│
├── FEV1 measured at 30 and 90 seconds after each 2-minute tidal breathing block
│
├── If FEV1 drops by ≥20% from post-diluent baseline ──► TEST TERMINATED (POSITIVE)
│ └── Calculate PC20 (Provocative Concentration)
│ └── Immediately administer 4 puffs Albuterol; monitor until FEV1 >90% baseline
│
└── If FEV1 does NOT drop by 20% at 16.0 mg/mL ────────► TEST TERMINATED (NEGATIVE)
└── Excludes active asthma with >95% Negative Predictive Value
Pharmacological Mechanism of Action

Methacholine (acetyl-beta-methylcholine chloride) is a synthetic choline ester that acts as a direct bronchial challenge agent . It resists rapid degradation by acetylcholinesterase and directly binds to muscarinic M3 receptors on airway smooth muscle cells, triggering smooth muscle contraction and bronchoconstriction. In normal individuals, the smooth muscle has high resting resistance and contracts minimally; in asthmatic individuals, smooth muscle hyperresponsiveness causes intense airway narrowing at very low concentrations.

Quantitative Diagnostic Thresholds: The PC20

The diagnostic result is expressed as the PC20 —the provocative concentration of methacholine that causes a 20% fall in FEV1 compared to the post-diluent baseline:

PC20 Threshold Diagnostic Category Clinical Interpretation
≤1.0 mg/mL Marked Airway Hyperresponsiveness Severe BHR; highly symptomatic active asthma
1.0 to 4.0 mg/mL Moderate Airway Hyperresponsiveness Definite asthma; frequent airway instability
4.0 to 8.0 mg/mL Mild Airway Hyperresponsiveness Diagnostic threshold for active asthma

8.0 to 16.0 mg/mL Borderline Airway Hyperresponsiveness Equivocal; seen in allergic rhinitis, COPD, or mild asthma

>16.0 mg/mL Normal Airway Responsiveness Negative Test; rules out active asthma (>95% NPV)

The High Negative Predictive Value (>95%): The primary clinical strength of a methacholine challenge is its ability to rule out active asthma . If a patient with chronic daily respiratory symptoms has a negative methacholine challenge (PC20 >16 mg/mL), active asthma is effectively excluded. The clinician must search for alternative diagnoses, such as vocal cord dysfunction (VCD/ILO), GERD, chronic bronchitis, bronchiectasis, or heart failure.

Safety Precautions and Absolute Contraindications

Methacholine testing intentionally provokes acute bronchospasm and must only be conducted in an accredited pulmonary function laboratory under physician supervision, with rapid-acting bronchodilators, oxygen, and full resuscitation equipment immediately available.

Absolute Contraindications:

Severe baseline airflow limitation: FEV1 <60% of predicted normal (or <1.5 L in adults) ;
Recent myocardial infarction or stroke within the prior 3 months;

Known aortic or cerebral aneurysm (forced maneuvers and acute bronchospasm spike thoracic and intracranial pressures);

Uncontrolled arterial hypertension: Systolic BP >200 mmHg or Diastolic BP >100 mmHg .

Relative Contraindications: Moderate airflow limitation (FEV1 <70% predicted); pregnancy and nursing (methacholine is FDA Category C); current use of cholinesterase inhibitors; recent viral respiratory infection within the prior 2 to 6 weeks (transiently induces non-specific bronchial irritability, yielding false-positive tests).

Allergy Testing Modalities: Skin Prick vs. Serum Specific IgE

Allergic asthma is the most prevalent asthma phenotype, accounting for over 80% of pediatric asthma and more than 50% of adult-onset cases. Demonstrating specific IgE sensitization to indoor perennial aeroallergens (dust mites, cockroaches, animal dander, molds) and outdoor seasonal pollens (trees, grasses, weeds) is essential to guide environmental trigger avoidance and direct allergen immunotherapy. Allergy Testing Diagnostic Comparison:

IN VIVO: Percutaneous Skin Prick Testing (SPT)
├── Introduces allergen extract into epidermis via lancet
├── Measures cutaneous mast cell degranulation (Wheal & Flare in 15–20 minutes)

├── Requires withholding oral antihistamines for 3 to 7 days!

└── Contraindicated in severe generalized eczema or active dermatographism

IN VITRO: Serum Allergen-Specific IgE (sIgE / ImmunoCAP)
├── Quantifies circulating allergen-specific antibodies in blood (kU/L)
├── Completely unaffected by antihistamines or tricyclic antidepressants
├── Safe in severe eczema, active urticaria, or extreme anaphylaxis risk
└── Higher financial cost and delayed laboratory turnaround time
1. Percutaneous Skin Prick Testing (SPT)

Technique: Standardized allergen extracts are placed on the volar surface of the forearm or upper back. A sterile lancet pricks the epidermal layer without inducing bleeding.

Controls: A positive histamine control (10 mg/mL) verifies skin reactivity; a negative saline/glycerin control rules out non-specific mechanical reactivity (dermatographism).

Interpretation: Read at 15 to 20 minutes . A test is positive if the allergen induces a wheal diameter ≥3 mm greater than the negative control, surrounded by erythema.

Medication Withholding: Oral H1-antihistamines suppress cutaneous histamine receptors, causing false-negative skin tests. Educators must verify that second-generation antihistamines (cetirizine, loratadine, fexofenadine) have been discontinued for 3 to 5 days , first-generation antihistamines (diphenhydramine) for 3 days, hydroxyzine for 5 to 7 days, and tricyclic antidepressants for 7 to 14 days.

2. Serum Allergen-Specific IgE Testing (sIgE)

Technique: Solid-phase in vitro immunoassays (e.g., ImmunoCAP) measure circulating allergen-specific IgE antibodies in serum, reported quantitatively in kU/L (with values ≥0.35 kU/L generally defining positive sensitization).

Key Clinical Advantages: sIgE is completely unaffected by concurrent antihistamines, oral steroids, or dermatologic medications. It is the method of choice for patients with severe active eczema, widespread psoriasis, dermatographism, or a history of life-threatening anaphylaxis to minute allergen exposures.

Advanced Diagnostic Modalities Comparison

Modality Biological Target Primary Indication Key Advantages Major Limitations Mandatory Pre-Test Preparation

FeNO Exhaled Nitric Oxide from iNOS activity Quantify Type 2 eosinophilic airway inflammation Non-invasive; rapid; predicts ICS responsiveness Suppressed by tobacco smoke; elevated by dietary nitrates Perform BEFORE spirometry; no nitrates/caffeine for 2–3 hours

Methacholine Challenge Smooth muscle M3 muscarinic receptors Evaluate airway hyperresponsiveness (AHR) >95% Negative Predictive Value to rule out active asthma Induces acute bronchospasm; specialized lab required Baseline FEV1 must be ≥60%; withhold bronchodilators

Skin Prick Testing (SPT) Cutaneous mast cell surface IgE Identify specific aeroallergen sensitizations Rapid (15–20 min); high sensitivity; low cost Risk of systemic reaction; suppressed by medications Withhold oral H1-antihistamines for 3 to 7 days

Serum Specific IgE (sIgE) Circulating allergen-specific IgE antibodies Identify aeroallergen sensitizations in vitro Safe in severe eczema; zero risk of anaphylaxis Higher laboratory cost; delayed turnaround time No medication withholding required